Nature Medicine Issues Expression of Concern on EZH2 Cancer Study

Nature Medicine Attaches a Formal Note to an EZH2 Study

Nature Medicine has published an Editorial Expression of Concern concerning a paper titled "SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2." The notice carries a publication date of 18 September 2026 and is indexed under the DOI 10.1038/s41591-026-04708-9.

The appearance of such a notice is a deliberate editorial act. It tells readers that a journal has become aware of something that affects how a published paper should be read, and it does so without asserting that the paper is wrong. The original article remains in the literature, its title and abstract unchanged, while the accompanying note alters the context in which researchers, clinicians, and science journalists should approach it. That distinction matters a great deal in a field where a single finding can shape drug-development programmes and shape which experiments laboratories choose to run next.

What an Expression of Concern Is — and What It Is Not

Editorial notices occupy a specific place in scientific publishing. Understanding the category is essential before drawing conclusions about any individual case.

• It is not a retraction. A retraction is a formal statement that a paper's findings cannot be relied upon. An expression of concern stops short of that, signalling doubt, ongoing investigation, or an unresolved dispute.
• It is not a finding of misconduct. The notice itself does not establish that anyone acted improperly. Investigations by institutions or by journals' own research-integrity teams follow separate procedures and produce their own reports.
• It is a signal to readers. Its practical function is to prevent the paper from being cited as settled evidence while questions remain open.
• It preserves the record. Rather than removing the article, the notice keeps it visible and links it to the journal's reservation — an approach that allows later readers to see the full sequence of events.

Journals typically issue these notices when the underlying facts are still being established, when authors and editors disagree about the significance of a problem, or when an institutional review has not yet concluded. The wording is usually cautious by design, because a more definitive statement could prejudice an investigation that is still running.

The Biology Behind the Flagged Paper

To understand why this notice will be noticed, it helps to understand the terrain the paper covers. The title references two well-studied systems in cancer epigenetics: the SWI/SNF chromatin-remodelling complex and the enzyme EZH2.

SWI/SNF, also known as the BAF complex, is a multi-subunit machine that uses the energy of ATP to move and evict nucleosomes — the protein spools around which DNA is wound. By repositioning those spools, the complex controls which stretches of the genome are accessible to the machinery that reads genes. Subunits of this complex rank among the most frequently mutated chromatin regulators in human cancer, and tumours carrying such mutations are often described as having a disordered regulatory landscape.

EZH2 is the catalytic subunit of Polycomb Repressive Complex 2, which deposits a methyl mark associated with gene silencing. It has long been studied as both an enzyme and a structural component of the complexes it inhabits, meaning it may influence gene expression in ways that do not depend solely on its catalytic activity. The phrase "non-catalytic activity" in the paper's title points directly at that second role.

The hypothesis implied by the title — that cancers lacking functional SWI/SNF components might become unusually reliant on EZH2, through both its enzymatic and its scaffolding functions — has been an influential idea in epigenetic research. It suggests a potential vulnerability that could be exploited therapeutically, and it links two areas of cancer biology that are each the subject of substantial drug-development effort. Work in this space carries weight precisely because it is translational: it speaks to whether a particular class of tumours might be treated by interfering with a specific chromatin regulator.

Why Researchers Will Be Paying Attention

Chromatin biology is an area where conclusions are hard-won. Dependency claims are typically supported by combinations of genetic screens, pharmacological inhibition, and animal models, each of which has known limitations. Reproducing a dependency relationship across cell lines and model systems takes time, and small differences in experimental conditions can produce divergent results.

An expression of concern attached to a high-profile paper in this area therefore has consequences beyond the paper itself. Laboratories may hesitate to build a research programme on the reported relationship until the situation is clarified. Reviewers may ask authors to justify citations to the work. Commentary that leaned on the finding could need revisiting. None of this means the science is invalid — only that the community treats the notice, correctly, as a reason to wait for resolution.

How to Read the Notice Responsibly

For anyone encountering this paper in a literature search or a citation list, a few practical guidelines apply.

• Read the notice itself rather than relying on second-hand summaries, and follow the DOI to check for updates or superseding statements.
• Do not treat the notice as evidence of error, fraud, or vindication of critics. It asserts none of those things.
• When citing the work, note that an expression of concern has been issued, so downstream readers are not misled about its standing.
• Watch for a subsequent editorial action, which may take the form of a lifted notice, a correction, a retraction, or a replacement paper.

The Larger Conversation About Research Integrity

Editorial notices of this kind have become more visible in recent years, in part because publishers now surface them on article pages, in indexing services, and in reference managers. That transparency is generally regarded as an improvement: readers are better served by knowing that a record is contested than by discovering it years later. It also places an obligation on journalists and institutions to describe notices accurately, without inflating them into verdicts.

The scientific literature is cumulative, and its self-correcting mechanisms depend on clear signposting. An expression of concern is one such signpost — a marker placed on the road, not a demolition of it.

What Comes Next

Nature Medicine has not, in the notice as published, terminated the paper's life in the record. Until the journal takes a further step, the appropriate posture for the research community is attentive patience: follow the DOI, track the authors' response if one is issued, and treat conclusions drawn from the paper as provisional.

Developments Today will continue to monitor the notice and report on any subsequent editorial action, correction, or clarification affecting the published record on SWI/SNF-mutant cancers and EZH2.

This article is based on reporting by Nature Medicine. Read the original article.